Eton Pharmaceuticals signs exclusive US license deal with Aquestive for Libervant seizure rescue film

Bitget2026/10/14 10:50

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Eton Pharmaceuticals signed an exclusive U.S. license and supply deal with Aquestive for LIBERVANT (diazepam) buccal film for seizure clusters.
Eton targets an April 2027 commercial launch, contingent on final FDA approval.
Full approval for patients 12 and older is expected after VALTOCO orphan exclusivity ends on Jan. 10, 2027.
A separate NDA to add ages 6-11 has a PDUFA action date of March 29, 2027.
Deal adds a neurology platform for Eton in a U.S. seizure rescue market estimated at more than $450 million annually.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eton Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610140650PRIMZONEFULLFEED9845294) on October 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Eton Pharmaceuticals signs exclusive US license deal with Aquestive for Libervant seizure rescue film

You may also like

Crypto prices